1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsInnovative Molecular Analysis Technologies (IMAT) Program (R61 and R33) is sponsored by National Cancer Institute (NCI). The IMAT program supports novel physical technologies, platforms, methods, or approaches for any field of cancer research. This includes early-stage and advanced development of technologies relevant to molecular analysis.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
About | Innovative Molecular Analysis Technologies (IMAT) Program - NCI Innovative Molecular Analysis Technologies (IMAT) Program Read the RFAs for novel technology development projects. Early-stage development of technologies: R61 Advanced development of technologies: R33 IMAT uses the R33 grant mechanism to support advanced development and validation of emerging technologies.
This mechanism is suitable for technologies that have preliminary data to demonstrate that major feasibility gaps have been overcome, but still require further development and rigorous validation for broad adoption by the research community.
Adoption of emerging technologies by research community: Competitive Revisions Through the competitive revision mechanism , currently funded NCI grantees with an R01, U01, or P50 award can apply for additional funds to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach developed through support from the IMAT program.
The PI of the R01, U01, or P50 who is receiving the revision award cannot be the IMAT-supported investigator; these projects are meant to provide independent validation of the emerging technologies and spur collaborations between tool developers and end users. History of the IMAT Program Technical innovation can improve and transform our ability to understand, prevent, diagnose, and treat cancer.
NCI established the IMAT program in 1998 to focus support on the development of innovative technologies that meet the specific needs of cancer researchers and clinicians and offer the potential to accelerate progress in the fight against cancer. The program promotes interdisciplinary research that brings diverse expertise to tackle persistent challenges in cancer research that are most in need of technical innovation.
Read about IMAT projects focused on the development of novel technologies for cancer research. By taking risks on early-stage technology development projects that have the potential to transform cancer research, IMAT has contributed to the development of many of the most widely used technologies across the cancer research and clinical communities.
MuDPIT , Rolling Circle Amplification , ROMA , Illumina bead platforms , and ICAT technologies were all supported by IMAT grants in the late 1990s. In the 2000s, IMAT supported development of activity-based protein profiling , PROTACS and numerous liquid biopsy , imaging mass spectrometry , single-cell analysis , and spatial -omic methods that are leading their fields today.
To encourage the adoption of emerging technologies by the research community, the IMAT program began soliciting proposals for competitive revisions to ongoing NCI research projects in 2018. This component of the program incentivizes independent validation of IMAT-supported technologies by early adopters of new technologies.
As new challenges emerge for cancer researchers and clinicians, the need for a technology development pipeline encompassing inception and initiation through dissemination and commercialization endures. The IMAT program serves a unique role at NCI in the early stages of this pipeline. The program is regularly evaluated by panels of external experts and subsequently evolves to meet the needs of the research community.
A summary of the findings from these evaluations can be found in CSSI’s Program Evaluation Reports page. Every year since 1999, all researchers with an active IMAT project have gathered for the annual IMAT PI meeting to share progress on their developing technologies and form collaborations. Information about these PI meetings going back to the inaugural meeting in 1999 can be found on CSSI’s Past Events page.
Dr. Kelly Crotty ( kelly. crotty@nih. gov ) Center for Strategic Scientific Initiatives Dr. Tony Dickherber ( dickherberaj@mail.
nih. gov ) Division of Cancer Biology Dr. Steven Becker ( steven. becker@nih.
gov ) Dr. Hannah Dueck ( hannah. dueck@nih. gov ) Dr. Cindy Kyi ( cindy.
kyi@nih. gov ) Division of Cancer Treatment and Diagnosis Diagnostic Biomarkers and Technology Dr. Asif Rizwan ( asif. rizwan@nih.
gov ) Dr. Jung Byun ( jung. byun@nih. gov ) Biorepositories and Biospecimen Research Dr. Ping Guan ( ping.
guan@nih. gov ) Dr. Lokesh Agrawal ( lokesh. agrawal@nih.
gov ) Dr. Yisong Wang ( yisong. wang@nih. gov ) Division of Cancer Prevention Dr. Vignesh Gunasekharan ( vignesh.
gunasekharan@nih. gov ) Dr. Nick Hodges ( nick. hodges@nih.
gov ) Division of Cancer Control and Population Sciences Dr. Stefanie Nelson ( stefanie. nelson@nih. gov )
According to the current listing, eligibility includes: Academic institutions, small businesses, and foreign organizations are eligible. (Early-stage and advanced development projects). Confirm the full requirements in the official notice before applying.
Innovative Molecular Analysis Technologies (IMAT) Program (R61 and R33) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article